The Claim
The Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio has diagnostic accuracy comparable to plasma p-tau217 alone, with a statistically significant improvement in overall performance (AUC 0.9457 vs. 0.9305, p=0.0010) and fewer indeterminate results, indicating that combining the two biomarkers into a ratio enhances diagnostic reliability.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
The ratio of pTau217 to β-Amyloid 1-42 in blood provides a more reliable diagnostic test for neurodegenerative conditions than pTau217 alone, with higher accuracy and fewer unclear results.
See the scientific wording
The Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio demonstrates diagnostic accuracy comparable to plasma p-tau217 alone, but with a statistically significant improvement in overall performance (AUC 0.9457 vs. 0.9305, p=0.0010) and fewer indeterminate results, indicating that combining the two biomarkers into a ratio enhances diagnostic reliability.
Measuring both p-tau217 and amyloid beta 1-42 together in blood lets doctors compare their levels directly, which cancels out random variations in how much each molecule appears in the blood, making it clearer when Alzheimer's disease is truly present.
What the research says
1 studyThis blood test that looks at two Alzheimer’s markers together (p-tau217 and amyloid beta) is more accurate than looking at just one of them, and it gives fewer unclear results. The numbers show it works better.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.